References
- 1. da Rocha Fernandes J, Ogurtsova K, Linnenkamp U, Guariguata L, Seuring T, Zhang P, et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract. 2016;117:48-54.10.1016/j.diabres.2016.04.016
- 2. Vazzana N, Ranalli P, Cuccurullo C, Davì G. Diabetes mellitus and thrombosis. Thromb Res. 2012;129(3):371-7.10.1016/j.thromres.2011.11.052
- 3. Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther. 2003;25(12):2991-3026.10.1016/S0149-2918(03)90089-0
- 4. Markowicz-Piasecka M, Huttunen K, Mateusiak L, Mikiciuk-Olasik E, Sikora J. Is metformin a perfect drug? Updates in pharmacokinetics and pharmacodynamics. Curr Pharm Des. 2017;23(17):2532-50.10.2174/138161282266616120115294127908266
- 5. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC, Goto S, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170(21):1892-9.10.1001/archinternmed.2010.40921098347
- 6. Ambelu YA, Shiferaw MB, Abebe M, Enawgaw B. Prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus: a comparative study. J Diabetes Metab Disord. 2018;17(2):117-21.10.1007/s40200-018-0347-5640540930918844
- 7. American Diabetes Association. Executive summary: Standards of medical care in diabetes - 2014. Diabetes Care. 2014;37:S5.10.2337/dc14-S00524357214
- 8. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. AJM. 2007;120(9):S12-7.10.1016/j.amjmed.2007.07.00317826041
- 9. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570-81.10.1001/jama.287.19.257012020339
- 10. Kumar A, Shanmugasundaram P. Development of a Validated Questionnaire to Assess Attitude of Patient to-wards Self-Management among uncontrolled diabetic population in Tamil Nadu. IJRPS. 2019;10(2):1089-95.10.26452/ijrps.v10i2.387
- 11. Johny SA, Anupriya AP, John O, Surekha G, Paarakh PM. Evaluation of pharmacoeconomics, medication adherence and quality of life in type 2 diabetes mellitus patients. IJRPS. 2017;8(3):315-20.
- 12. Hasslacher C, Collenberg E, Möcks J. Effect of insulin analogs on the decline of hemoglobin in diabetic patients with nephropathy. Exp Clin Endocrinol Diabetes. 2010;118(06):341-5.10.1055/s-0029-124182620112184
- 13. Teliga-Czajkowska J, Sienko J, Zareba-Szczudlik J, Malinowska-Polubiec A, Romejko-Wolniewicz E, Czajkowski K. Influence of glycemic control on coagulation and lipid metabolism in pregnancies complicated by pregestational and gestational diabetes mellitus. Adv Biomed. 2019:81-8.10.1007/5584_2019_38231069723
- 14. Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertility and sterility. 2017;108(3):426-41.10.1016/j.fertnstert.2017.06.02628865539
- 15. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(01):27-31.10.1055/s-0032-1327734